What is new in the management of rapidly progressive glomerulonephritis? (original) (raw)

“…Treatment for RPGN relies on supportive care, glucocorticoids and cyclophosphamide. Plasmapheresis is the standard treatment for anti‐GBM disease with favorable clinical outcomes, and an additional treatment for ANCA‐associated vasculitis, producing reduction in the risk of ESRD (relative risk, 0.64) . In this study, despite the increased rate of cyclophosphamide treatment and availability of plasmapheresis during 2008–2014, renal outcome was not different to the prior period (1997–2007).…”

Section: Discussionmentioning

See 1 more Smart Citation

“…Treatment for RPGN relies on supportive care, glucocorticoids and cyclophosphamide. Plasmapheresis is the standard treatment for anti‐GBM disease with favorable clinical outcomes, and an additional treatment for ANCA‐associated vasculitis, producing reduction in the risk of ESRD (relative risk, 0.64) . In this study, despite the increased rate of cyclophosphamide treatment and availability of plasmapheresis during 2008–2014, renal outcome was not different to the prior period (1997–2007).…”

Section: Discussionmentioning

“…Plasmapheresis is the standard treatment for anti-GBM disease with favorable clinical outcomes, and an additional treatment for ANCA-associated vasculitis, producing reduction in the risk of ESRD (relative risk, 0.64). [21][22][23] In this study, despite the increased rate of cyclophosphamide treatment and availability of plasmapheresis during 2008-2014, renal outcome was not different to the prior period (1997)(1998)(1999)(2000)(2001)(2002)(2003)(2004)(2005)(2006)(2007). This may be due to the low number of patients with anti-GBM disease or ANCA-associated vasculitis who received the treatment.…”

Section: Discussionmentioning

“…CGN, also known as rapidly progressive glomerulonephritis, is characterized by glomerular necroinflammation and crescent formation . Mulay et al have demonstrated that MDM2 drives CGN through both p53‐dependent and p53‐independent pathways.…”

Section: Roles Of Mdm2 In Inflammation and Autoimmune Diseasesmentioning

“…Importantly, when discussing RPGN, a number of entities are frequently included in case series and trials, thus confounding results . Therapy consists of administration of high‐dose corticosteroids (e.g., methylprednisolone) and cytotoxic immunosuppressive drugs (e.g., cyclophosphamide or azathioprine) . Other drugs used include leflunomide, deoxyspergualin, tumor necrosis factor blockers, calcineurin inhibitors, and antibodies against T cells .…”

Section: Nephrological Disorders: Rapidly Progressive Glomerulonephritismentioning

“…The following therapy recommendation is based on the few uncontrolled and controlled studies available . TA is indicated in combination with an immunosuppressive therapy with prednisolone (intravenous pulse therapy, or oral therapy), cyclophosphamide (intravenous pulse therapy or oral therapy), or azathioprine in indicated in the following cases:

RPGN with serum creatinine under 5.8 mg/dL without oliguria in anti‐GBM disease All severe forms of RPGN with or without ANCA ab, like the pauci‐immune complexes, (Cr >6 or patient on dialysis) Goodpasture syndrome with life‐threatening hemoptysis, or diffuse alveolar hemorrhage from ANCA or MPA independent of renal function status Preparation for kidney transplant with anti‐basement membrane antibodies still detectable in the serum.

…”

Section: Immune Complex Nephritismentioning